Rheumatoid arthritis (RA) is a chronic autoimmune condition in which the immune system attacks the joints, causing inflammation, pain, swelling, and eventually joint damage. It affects approximately 400,000 people in the UK — about 1 in 100 adults — and is 3 times more common in women than men. RA most commonly develops between ages 40–60, but can occur at any age. With modern treatments, including targeted biological and JAK inhibitor therapies available on the NHS, most people with RA can achieve remission or low disease activity and lead full, active lives.
Symptoms of Rheumatoid Arthritis
RA typically causes symmetrical joint involvement — if one hand is affected, so is the other. Common symptoms include:
- Joint pain, swelling, and warmth — particularly in small joints of the hands, wrists, and feet in early disease
- Morning stiffness — lasting more than 30 minutes (a key distinguishing feature from osteoarthritis, where stiffness resolves quickly)
- Fatigue — often severe and debilitating; one of the most impactful symptoms for quality of life
- Fever and feeling generally unwell — particularly during flares
- Joint deformity — in later disease; characteristic “ulnar deviation” of fingers
- Reduced grip strength
Extra-articular manifestations (outside the joints) can include: rheumatoid nodules (firm lumps under the skin), pleuritis (lung lining inflammation), pericarditis (heart lining inflammation), dry eyes and mouth (secondary Sjögren’s), vasculitis, and anaemia.
Diagnosis
NICE guideline NG100 recommends urgent referral to a rheumatologist within 3 weeks if a person has any small joint swelling, or within 6 weeks if there is suspected RA without small joint involvement but with synovitis (joint inflammation). Early diagnosis and treatment is critical — joint damage can begin within weeks of disease onset.
Blood Tests
- Rheumatoid Factor (RF) — positive in ~70% of RA patients; but not specific (also positive in other conditions and in 5–10% of healthy people)
- Anti-CCP antibodies (anti-cyclic citrullinated peptide) — more specific than RF; positive in ~70% of RA; associated with more aggressive, erosive disease; can be positive years before symptoms
- CRP and ESR — markers of inflammation; used to monitor disease activity
- FBC, LFTs, U&Es — baseline tests before starting DMARDs
Imaging
- X-rays — baseline assessment; may show erosions in established disease
- Ultrasound — detects synovitis and erosions earlier than X-ray; widely used in UK rheumatology clinics
- MRI — most sensitive for early erosions and synovitis; used in specialist centres
NHS Treatment for Rheumatoid Arthritis
The goal of RA treatment is “treat-to-target” — achieving remission (DAS28 <2.6) or low disease activity (DAS28 <3.2). DAS28 is a composite disease activity score using joint counts, ESR/CRP, and patient global assessment.
Step 1: Conventional DMARDs (First-Line)
NICE recommends starting a conventional DMARD within 3 months of RA onset — methotrexate is the anchor drug:
- Methotrexate — once-weekly oral or subcutaneous injection; the most widely used DMARD globally; requires folic acid supplementation; regular blood monitoring (FBC, LFTs)
- Hydroxychloroquine — mild disease or in combination; annual eye checks recommended after 5 years
- Sulfasalazine — often used in combination; requires G6PD testing in some ethnicities
- Leflunomide — alternative to methotrexate
- Combination DMARD therapy — NICE recommends considering triple therapy (methotrexate + hydroxychloroquine + sulfasalazine) or dual therapy as first-line for active disease
Step 2: Biological DMARDs (bDMARDs)
If two conventional DMARDs have failed (after adequate trials of at least 6 months each), NICE approves biological therapies. These are typically used alongside methotrexate:
- TNF inhibitors — adalimumab (Humira), etanercept (Enbrel), certolizumab (Cimzia), golimumab (Simponi); self-injected fortnightly or monthly; most widely prescribed biologics in UK RA
- Abatacept (Orencia) — T-cell co-stimulation inhibitor
- Rituximab (MabThera) — B-cell depleter; IV infusion; NICE preferred for RF/anti-CCP positive RA or where TNF inhibitors have failed
- Tocilizumab (RoActemra) — IL-6 receptor antagonist; can be used as monotherapy (without methotrexate)
- Sarilumab (Kevzara) — IL-6 inhibitor; self-injected fortnightly
Step 3: JAK Inhibitors (Targeted Synthetic DMARDs)
JAK inhibitors are oral targeted therapies — a major advance in RA treatment offering the convenience of tablets over injections:
- Baricitinib (Olumiant) — NICE approved; once-daily tablet
- Tofacitinib (Xeljanz) — NICE approved for moderate-severe RA after methotrexate failure
- Upadacitinib (Rinvoq) — NICE approved 2021; highly effective; once-daily tablet
- Filgotinib (Jyseleca) — NICE approved
Note: Following a large EU safety study (ORAL Surveillance), the MHRA and EMA recommend JAK inhibitors be used with caution in patients over 65, smokers, or those with cardiovascular risk factors — a recent UK regulatory update worth discussing with your rheumatologist.
Bridging Therapy: Steroids
Short courses of prednisolone or steroid injections (intramuscular or intra-articular) are used to control flares rapidly while DMARDs take effect. Long-term oral steroids should be avoided due to side effects including osteoporosis, diabetes, and infection risk — all patients on long-term steroids should be on bone protection therapy.
Cardiovascular Risk in Rheumatoid Arthritis
People with RA have approximately 50% higher cardiovascular risk than the general population — due to systemic inflammation accelerating atherosclerosis. NICE recommends annual cardiovascular risk assessment using a modified QRISK calculation (the risk score is multiplied by 1.5 for people with RA). Control of disease activity, smoking cessation, blood pressure and cholesterol management, and statin therapy are important components of RA management. See our hypertension guide and cholesterol guide.
Living Well With Rheumatoid Arthritis
- Occupational therapy — joint protection techniques, splints, adaptive equipment; available via NHS rheumatology teams
- Physiotherapy — exercise reduces joint damage and fatigue; hydrotherapy may help
- NRAS Helpline and self-management programmes
- Smoking cessation — smoking worsens RA disease activity and is a risk factor for developing RF-positive RA
- Flu and pneumococcal vaccination — essential for immunosuppressed patients on DMARDs; do not have live vaccines while on biologic therapy
- Regular monitoring — 3-monthly blood tests while on DMARDs; DAS28 assessment at every clinic appointment
UK Support and Resources
- NRAS (National Rheumatoid Arthritis Society) — nras.org.uk | Helpline: 0800 298 7650 | UK’s largest RA charity
- Versus Arthritis — versusarthritis.org | Helpline: 0800 5200 520 | Support for all types of arthritis
- British Society for Rheumatology (BSR) — rheumatology.org.uk | NICE-endorsed clinical guidelines
- NICE NG100 — Rheumatoid arthritis in adults: management — nice.org.uk
What Major Health Sites Often Miss About Rheumatoid Arthritis
1. Cardiovascular Risk Is the Leading Cause of Early Death in RA
Most US and international health sites focus on joint damage as the primary RA concern. In the UK, NICE explicitly recommends annual cardiovascular risk assessment with a modified QRISK score (multiplied by 1.5) for all RA patients. Heart disease — not joint destruction — is the main cause of premature mortality in RA. Effective treatment of RA itself (which reduces systemic inflammation) plus aggressive cardiovascular risk factor management are both essential — this dual approach is central to UK rheumatology practice but frequently overlooked in patient education materials.
2. Rituximab as a Preferred Second-Line Biologic for Seropositive RA
The UK’s cost-effectiveness analysis has led NICE to specifically recommend rituximab as a preferred option for RF-positive or anti-CCP-positive RA after TNF inhibitor failure — due to its lower cost and comparable efficacy. US guidelines don’t make this specific distinction. NHS prescribing practice thus differs meaningfully from US practice in the sequencing of biologics, which matters for patients comparing information across different countries.
Related Health Guides on YourHealthXpert
- Arthritis Guide — overview of all types of arthritis including osteoarthritis and RA
- Osteoporosis — RA and corticosteroid treatment significantly increase osteoporosis risk
- High Blood Pressure — cardiovascular risk management is essential in RA
- High Cholesterol — statin therapy is often indicated in RA for cardiovascular protection
- Anxiety and Depression — mental health conditions are significantly more common in people with chronic pain conditions